Načítá se...
A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types of cancers, which plays a vital role in the cancer progression. Monoclonal antibodies targeting Her2 are now used in the clinic to treat Her2 overexpression cancer p...
Uloženo v:
| Vydáno v: | Transl Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Neoplasia Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5852409/ https://ncbi.nlm.nih.gov/pubmed/29455083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2018.01.024 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|